DOCSLIB.ORG

Introduction List of Contributors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction List of Contributors Introduction List of contributors (alphabetically) 3M Apparel Group AB Food and Beverages Australia Apple Australia AB Mauri AREVA T&D Australia ABB Australia Aristocrat Technologies Australia Abbott Australasia Arrow Electronics Australia Accenture Australia ASC Accolade Wines Ascott International Management (Australia) Actelion Pharmaceuticals Aspen Pharmacare Australia Adelaide Brighton Astellas Pharma AECOM Australia AstraZeneca Aesop AT & T Global Network Services Australia Agilent Technologies Australia Atlassian AGL Energy Aurora Energy AGR Field Operations Ausclad Group of Companies Alcatel-Lucent Australia Ausenco Alcon Laboratories Australia Ausgrid (Formerly EnergyAustralia) Alexion Pharmaceuticals Aussie Home Loans Alfa Laval Australia Aust Lubricants Manufacturing Co Allergan Australia Australand Alphapharm Australian Agricultural Company Alstom Australian Football League Altium Autodesk Amadeus IT Pacific Avanade, Inc. Ambulance Victoria Avery Dennison Office and Consumer Products Amcor AVJennings Amdocs Avon Cosmetics AMEC Minproc AWB Amgen Australia Barbeques Galore AMP Services BASF Australia Amway (Alticor Inc) Baulderstone Anglican Retirement Villages Diocese of Sydney Baxter Healthcare ANL Container Line Bechtel Australia APL Lines Australia Becton Dickinson Australia Apotex Best & Less © September 2011 Mercer (Australia) Pty. Ltd. Quarterly Salary Review 1.5 Introduction BIC Australia Campari Australia Big W Campbell Arnott’s Biogen Idec Australia Cargill Australia Biomin Cargotec Australia Bio-Rad Laboratories CargoWise Biota Holdings Carl Zeiss Vison Black and Veatch Australia Carnival Plc BMC Software Carter Holt Harvey BMW Group Australia Caterpillar of Australia Boart Longyear CBI Constructors BOC CCH Australia Boeing Aerostructures Australia (BAA) Centro Properties Group Bombardier Transportation Australia Executive Century Yuasa Batteries Data Cerner Borouge Australia CH2M HILL Australia Boston Scientific ANZ Chamberlain Australia BP Australia Checkpoint Systems Brambles Christian Dior Australia Bridgestone Australia Chrysler Australia Brightstar Logistics Cisco Systems Australia Brightwater Care Group Clarke Equipment Australia Brisbane City Council Clorox Bristol-Myers Squibb Australia Clough Bristow Group Clyde Babcock-Hitachi (Australia) British American Tobacco Australia Coca-Cola Amatil Brivis Climate Systems Cochlear Broadcast Australia Cognis Australia Brookfield Office Properties Coles Group BRP Australia Colgate-Palmolive BSH Collins Restaurants Management BT Australasia Colonial First State Property Management BTG Australasia ComfortDelGro Cabcharge Bunge Agribusiness Australia Commercial Eyes Bupa Australia Health Commonwealth Bank of Australia CA Pacific Connell Bros Company Australasia Cadbury Conneq Infrastructure Services (Australia) Callaway Golf South Pacific Control Component Inc 1.6 Quarterly Salary Review © September 2011 Mercer (Australia) Pty. Ltd. Introduction Co-operative Bulk Handling Ego Pharmaceuticals Corning Cable Systems Electronic Arts Corporate Express Australia Eli Lilly Australia Coty Australia EMC Australia Country Road Emerson Network Power Australia Covance Emerson Process Management ANZ Covidien Emerson Stewart Cricket Australia Enerflex Australasia Holdings CSL ENERGEX Cummins South Pacific Energizer Australia Cuscal Energy Safe Victoria Cytec Australia Holdings Epic Energy Dalkia Technical Services Equant Integration Services Danfoss equigroup Davey Products Equinix Australia David Jones Exego Group Deb Australia fairfaxdigital Delaware North Companies Australia Federal Court of Australia Dell Australia Ferrero Australia Department of Internal Affairs Ferring Pharmaceuticals DFS Financial Services Institute of Australia DHL Express (Australia) First Data Australia DHL Global Forwarding FleetPartners DHL Supply Chain (Australia) Flint Group Diageo Fluor Corp Diaverum Australia Fonterra Australia Dick Smith Ford Motor Company of Australia Diversey Australia Ford of Australia – Product Development DOF Subsea Fossil (Australia) Donaldson Australasia Freehills Dow Chemical (Australia)Downer EDI Fresenius Kabi Australia DS Australia Fresh Start Bakeries Australia DSM Nutritional Products Australia G & S Engineering Services DST Global Solutions Galderma Australia DTS Food Laboratories Gambro Dun & Bradstreet (Australia) Ecolab Gardner Denver Edwards Lifesciences Garlock © September 2011 Mercer (Australia) Pty. Ltd. Quarterly Salary Review 1.7 Introduction GBC Fordigraph HJ Heinz Co Australia GE Healthcare Australia Honeywell Holdings General Cable Hospira Australia General Mills HRL General Pants Group Hugo Boss Australia Genworth Financial Husqvarna Australia Geodis Global Solutions Australia Hyder Consulting Geraldton Fishermen’s Cooperative IBM Australia GHD IDC Australia Giesecke & Devrient Australasia IKEA Gilead Sciences IMI Cornelius (Australia) Givaudan Imperial Tobacco Australia GlaxoSmithKline Holdings IMS Health Australia GM Holden Infigen Energy Services GN Netcom Australia Ingram Micro Australia Goodyear & Dunlop Tyres Australia iNova Pharmaceuticals (Australia) Google Insurance Australia Group GrainCorp Intec Billing Australia Griffith Hack Intel Australia Grocon InterContinental Hotels Group Growthpoint Properties Australia Invensys Grundfos Pumps Invida Australia GTA Australasia INVISTA (Australia) Guerlain Ipoh Management Services Hannover Life Re of Australasia Ipsen Hapag-Lloyd (Australia) ISELECT Harley-Davidson Australia iSOFT Health Hasbro Inc ITT Water & Wastewater Australia Hastie Holdings Jacobs E&C Australia Hatch Associates Jemena Hempel (Australia) John Bean Technologies Australia Henkel – Cosmetics Division John Crane Australia Henkel Australia John Deere Herbalife Australasia John Holland Group Hewlett-Packard Australia Johnson & Johnson Medical Hilton Worldwide Johnson & Johnson Pacific Hitachi Data Systems Johnson Screens (Australia) 1.8 Quarterly Salary Review © September 2011 Mercer (Australia) Pty. Ltd. Introduction Jones Lang LaSalle Macdonald Johnston Engineering Co Juniper Networks Australia Macmahon Contractors Kao (Australia) Marketing Maersk Australia and APM Global Logistics Australia Kao Brands Company Mallesons Stephen Jaques Kellogg (Aust.) Manassen Foods Australia Kellogg Brown & Root Manpower Services (Australia) Kennametal Australia Mars Australia Kimberly-Clark Mary Kay Cosmetics Klinger MasterCard Australasia KMART Australia Mattel Kodak (Australasia) Mayne Pharma International KONE Elevators McCain Foods (Aust) Kraft Foods Australia McConnell Dowell Corporation L-3 Communications Australia McDermott International, Inc. Laing O’Rourke Australia Construction MeadWestvaco Land Management Corporation Meat & Livestock Australia Latrobe Health Services Media Monitors Lawson Software Medtronic Australasia Leica Biosystems Melbourne Racing Club Leighton Contractors Mentholatum Australasia Lend Lease Merck Serono Australia Lenovo Metalsa Australia LexisNexis Australia Metcash Trading Lexmark International Michael Hill Jeweller LG Electronics Michell Life Technologies Australia Micron Semiconductor Australia Lion Nathan Microsoft Logicamms Millipore Australia Lonely Planet MiTAC Australia L’Oréal Australia Mitsubishi Motors Australia Louis Vuitton Australia Moét Hennessy Australia Lundbeck Australia Monadelphous Group Luxottica Retail Australia Mondial Assistance LVMH – P&C Monsanto LVMH – P&C LVMH Fragrances Moog Australia LVMH Watch and Jewellery Australia Motorola Mobility Australia MAB Corporation © September 2011 Mercer (Australia) Pty. Ltd. Quarterly Salary Review 1.9 Introduction MSD Origin Energy Muir Electrical Oyster Bay Wines Australia Mundipharma Pacific Internet (Australia) Munich Holdings of Australia Pall Australia Myer Holdings Pandora Jewelery Nacap Australia Paramount HE AUS Nalco Australia Parexel International Corporation National Australia Bank Parmalat Pacific Holdings National Credit Management Parsons Brinckerhoff Australia NBN Co Patties Foods NCSI (Australia) PepsiCo Australia & New Zealand Nestlé Australia Pfizer Australia Network Appliance, Inc. (Australia) Pharmaxis Newell Rubbermaid Philip Morris NICE Philips Electronics Australia Nissan Motor Company Australia Pioneer Hi-Bred Australia NLC Polycom Australia Nokia Australia PPG Architectural Coatings Nokia Siemens Networks Australia PPG Industries Australia Norfolk Group Holdings Procter & Gamble Norgine Programmed Group Norton Rose Australia PZ Cussons Novartis Australasia QGC Novartis Ciba Vision Australia Queensland Sugar Novartis Pharmaceuticals Australia Quintiles Novo Nordisk Pharmaceuticals RAA of SA Incorporated Novotech Australia RAC WA Novozymes Racing & Wagering WA Nuplex Industries (Aust) Railways Credit Union Nutricia Australia Raytheon Australia Nutrimetics Australia RCI Pacific Nycomed Readers Digest (Australia) Officeworks Rebel Group Oliver J Nilsen Reckitt Benckiser (Australia) Omron Electronics Red Bull Australia Oracle Corporation Australia Red Hat Orica Research In Motion (RIM) 1.10 Quarterly Salary Review © September 2011 Mercer (Australia) Pty. Ltd. Introduction ResMed Smiths Medical Australasia, Revlon Australia SMS Management and Technology Rheem Australia Solutia Australia Rinnai Australia Sony Ericsson Mobile Communications International AB Robert Bosch (Australia) Spark Infrastructure Roche Products Spirax Sarco Rockwell Automation SPLM Australia Roger Seller and Myhill Spotless Group Roland DG Australia St John Ambulance Australia Rolls-Royce Australia Service, Rolls-Royce (Western Australia) Inc Australia
Load more

Recommended publications
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • The Confusions in Nordic ESG Ratings
    Rating Objectivity: The Confusions in Nordic ESG Ratings ESG Ratings Subjectivity and its Consequences MASTER THESIS WITHIN: Business Administration NUMBER OF CREDITS: 30 ECTS PROGRAM OF STUDY: Civilekonom AUTHOR: John Rydholm & Samuel Schultzberg Bagge TUTOR: Fredrik Hansen & Toni Duras JÖNKÖPING May 2020 Master Thesis within Business Administration Title: Rating Objectivity: The Confusions in Nordic ESG Ratings - ESG Ratings Subjectivity and its Consequences Authors: John Rydholm, Samuel Schultzberg Bagge Tutors: Fredrik Hansen, Toni Duras Date: May 2020 Key terms: ESG, CSR, Ratings, Rating agencies, MSCI, Thomson Reuters, Sustainalytics, RobecoSAM Abstract: Environmental, Social and Governance measurements have significantly increased in usage due to growing concerns for environmental and sustainability problems in today’s world. However, with no commonly agreed-upon criteria for ESG ratings, the scoring measure creates confusion both at the investor and company level. Besides, ESG agencies have different processes and parameters for measuring ESG compliance, which contributes to the problem. The study examines four ESG rating agencies’ rating models and ESG scores to get a better understanding of deviations in ESG scores among Nordic companies. By also studying the correlation amongst ESG scores and market capitalizations in firms, the paper hopes to shed light on if any relationships exist between them. Our results show that the four major ESG raters in the study showed a weak to a non-significant correlation against each other. The maximum correlation found was 0.419 between Thomson Reuters and MSCI. RobecoSAM and MSCI showed the lowest significant correlation at 0.291. Sustainalytics was detected not to show any significant correlation with the other raters.
    [Show full text]
  • Novo Nordisk Annual Report 2012
    novo nordisk annual report 2012 Diabetes – an emergency in slow motion Strategy Sustainable growth is all about – can it be done? choice Insulin in Novo Nordisk’s performance in 2012 is a result of important decisions made in recent years a tablet – but there is more to the story – why is it so difficult? Contents Accomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlook Our business 15 Strategy is all about choice 20 Diabetes – an emergency Diabetes – an emergency in slow motion 20 in slow motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet – why is it so difficult? 28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets – one model 38 Sustainable growth – can it be done? 41 With every big opportunity comes a risk Governance, leadership and shares 44 Shares and capital structure The protein 46 Corporate governance 22 powerhouse 49 Remuneration 52 Board of Directors 54 Executive Management Financial, social and environmental statements 55 Consolidated financial, social and environmental statements 104 Financial statements of the parent company 109 Management’s statement and Auditor’s reports Additional information 112 More information Simple 28 injections 113 Product overview The Management review, as defined by the Danish Financial Statements Act (FSA), is found on pp 1–54 and 94. This Annual Report is published in both a Danish and an English language version. In the event of any discrepancies, the Danish version shall prevail. 1 Chairman of the Board of Directors Sten Scheibye at the Annual General Meeting in March 2012.
    [Show full text]
  • Ifu Project Portfolio 2018 2 | Ifu Project Portfolio 2018
    IFU PROJECT PORTFOLIO 2018 2 | IFU PROJECT PORTFOLIO 2018 PROJECT Portfolio INDEPENDENT AUDitors’ report ON IFU PROJECT Portfolio 2018 Up to the end of 2018, IFU and IFU managed funds had co-financed To the Executive Board of IFU standards, applicable requirements in Danish law and other regulations. a total of 1,286 projects in 101 countries. Of these, 203 are ongoing As agreed, we have examined the IFU Project Portfolio 2018. The IFU We complied with independence requirements and other ethical stand- investments, while IFU has exited 1,083 projects. The distribution of Project Portfolio 2018 has been listed and presented in accordance with ards under FSR - Danish Auditors’ Code of Ethics for Professional all projects by region is illustrated in the figure below. the methodology and definitions described in “Note to IFU’s project Accountants, which rely on general principles regarding integrity, ob- portfolio – definitions (only in English)”. jectivity, professional competence and due care, confidentiality and professional conduct. TotAL NUMBER OF projects DistriButeD BY REGION We are to conclude on IFU Project Portfolio 2018 to ascertain whether the data and information are correctly reflected in accordance with the As part of our examinations, we performed the below procedures: methodology and definitions reflected in “Note to IFU project portfolio • A sample check of whether IFU’s recordings of the individual share Africa 278 –definitions”. The IFU Project Portfolio 2018 means IFU’s involvement capital investments/project loans, total disbursed and expected total Asia 422 in active and finalised projects, as presented by the Executive Board and investment are reconciled in accordance with the contractual frame- Europe 445 in accordance with the principles and definitions reflected in “Note to work and information provided.
    [Show full text]
  • TO the SHAREHOLDERS of H. LUNDBECK A/S NOTICE of ANNUAL GENERAL MEETING Notice Is Hereby Given of the Annual General Meeting Of
    TO THE SHAREHOLDERS OF H. LUNDBECK A/S NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the Annual General Meeting of H. Lundbeck A/S to be held on: Thursday, 21 March 2013 at 10:00 AM The Annual General Meeting will be held at the Company’s address: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby Agenda In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as fol- lows: 1. Report of the Board of Directors on the Company's activities during the past year. 2. Presentation and adoption of the annual report. 3. Approval of remuneration for the Board of Directors for the current financial year. 4. Resolution on the appropriation of profit or loss as recorded in the adopted annual report. 5. Election of members to the Board of Directors. 6. Election of one or two state-authorised public accountants. 7. Any proposal by shareholders or the Board of Directors. 8. Any other business. Complete proposals Re agenda item 1: The Board of Directors recommends that the report should be adopted. Re agenda item 2: It is proposed that the annual report should be adopted. Re agenda item 3: It is proposed that the remuneration for the Board of Directors for the current financial year should be the same as in 2012: - Ordinary members will receive a basic remuneration of DKK 300,000 - The chairman will receive three times the basic remuneration - The deputy chairman will receive two times the basic remuneration - Ordinary members of the Audit Committee, the Remuneration Committee and the Scien- tific Committee will receive DKK 200,000 in addition to the basic remuneration - The Committee chairmen will receive DKK 300,000 in addition to the basic remuneration Re agenda item 4: It is proposed that a dividend of 35% of the net profit for the year, corresponding to DKK 2.00 per share, or a total dividend of DKK 392 million, should be distributed for the financial year 2012.
    [Show full text]
  • Financial Results & Business Update Q1 2021
    Financial results & business update Q1 2021 11 MAY, 2021 COMPANY DISCLAIMER This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses. The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation.
    [Show full text]
  • Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
    GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • Lundbeck Continues to Deliver Solid Growth for Strategic Brands and the Financial Guidance Range Has Been Updated
    Corporate Release Valby, Denmark, August 18, 2021 Financial report for the period January 1 to June 30, 2021 Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated HIGHLIGHTS Revenue reached DKK 8,233 million in the first half of 2021, a decline of 4% in local currencies because of generic erosion on Northera®. EBIT grew 58% compared to the same period in 2020 and reached DKK 1,478 million. EBIT margin reached 18.0%. EPS grew by 63% for the period, reaching DKK 5.03. In aggregate, strategic brands grew 13% in local currencies reaching DKK 4,408 million in the first half of the year or 54% of total revenue. In the second quarter of 2021, all strategic brands have resumed double-digit growth in local currencies. Based on trends in Trintellix and Rexulti, there is a gradual uptick in new patient starts supporting growth momentum. The newest product in the portfolio, Vyepti®, continues its strong momentum since launch in April 2020 and reached DKK 101 million in the second quarter of 2021 compared to DKK 14 million for the same period last year. Regulatory review is ongoing in 14 markets. Strategic brand performance: ➢ Revenue of Abilify Maintena®: DKK 1,197 million (up 5% in local currencies, +2% reported) ➢ Revenue of Brintellix®/Trintellix®: DKK 1,656 million (up 12% in local currencies, +5% reported) ➢ Revenue of Rexulti®/Rxulti®: DKK 1,378 million (up 9% in local currencies, -1% reported) ➢ Revenue of Vyepti®: DKK 177 million (up 1,245% in local currencies, +1,164% reported) Market performance: ➢ Revenue in North America: DKK 4,052 million (down 10% in local currencies, -17% reported) ➢ Revenue in International Markets: DKK 2,197 million (up 6% in local currencies, -1% reported) ➢ Revenue in Europe: DKK 1,729 million (up 3% in local currencies, +2% reported) In connection with the financial report, Lundbeck’s President and CEO Deborah Dunsire said: “I am proud of our performance and our solid financial results as the strategic brand growth accelerates post pandemic.
    [Show full text]
  • The Future of Business Using Enterprise Server
    Market Review Market Review Paper by Bloor Author David Norfolk Publish date June 2021 The Future of Business …using Enterprise Server 3.0 Services A company has to stay“ in business while modernising its systems and any modernisation must have a clearly documented business case and properly managed risk. What this means is that migrating a working system to a new platform may not be a good use of resources, especially as alternative modernisation options (such as the provision of cloud APIs or Application Programming Interfaces) are available. ” Executive summary he Future of Business will Well, the nub of the business issue we be largely built on the past, spotlight here is that migration to Cloud T for existing companies. is often recommended simplistically as Modernisation of what you have already, a platform for future business, almost as presumably “fit for current purpose” (or you a fashion option, with implied promises wouldn’t be in business) avoids waste and of ultimate agility, elastic capabilities mitigates certain classes of risk (although, without limits and low cost; but the if not done properly, it can add new risks). actuality is often different – and never Modernisation, of course, implies fit for quite being able to complete a migration evolution and change – once modernised, off Enterprise Server 3.0, because the you will be making further changes to business realities won’t let you, is accommodate new business. probably the most expensive scenario Modernisation of what For big enterprises, the world still runs of all. Cloud provides a wide choice of you have already,“ on very large, very resilient, servers – often platforms, some with innovative and presumably “fit for current referred to as “mainframes”, although attractive characteristics, but three truths Bloor prefers the term Enterprise Server remain important: purpose” (or you wouldn’t be in business) avoids 3.0.
    [Show full text]
  • Company Note
    Meet - the Equity Research - management event in managementBoston in event Investment Research Company update 8 February 2017 Novo Nordisk Buy (Unchanged) Pharmaceuticals, Denmark Meet-the-management event in Boston Key data On the day of the FY release, there was much focus on risks due to the changed Price (DKK)* 234 Target price, 12 mth (DKK) † 300 guidance range. The meet-the-management event in Boston on Tuesday had Market cap (DKKm) 606,998 more focus on opportunities. Our impression is that management is talking more Market cap (EURm) 81,652 towards the high end of guidance but that the low end was changed if something Reuters NOVOb.CO unexpected (not very likely) should occur. We keep our DKK300 12M TP and Buy. Bloomberg NOVOB DC No. of shares (m) 2,599.6 Clearer message. Novo has had time to digest how its FY release was received Net debt (current Y/E) (m) -14,353 and its communication has become clearer. The EBIT guidance of -2% to +3% Free float 73.0% Avg. daily vol, 12M (000) 3,376.6 growth in 2017 includes a 4% headwind from Vagifem generics and a tough Norditropin comp. Adjusting for this implies 2-7% growth, which makes it Price performance 400 380 comfortable to deliver 5%-plus after 2017. Cost savings in 2017 from layoffs in 2016 360 340 come to DKK1bn and Novo is set to save a further DKK500m from procurements 320 300 280 in 2017 (and 2018) – savings that have been invested in other parts of Novo. 260 240 220 US.
    [Show full text]
  • PP Hemmingsen
    Lundbeck Foundation EU conference: Giving more to research in Europe Presentation by Steen Hemmingsen, Managing Director, The Lundbeck Foundation - The Danish research funding system - The Danish foundation sector a. Charitable b. Industrial c. Dual purpose (Commercial Foundation Act) - The Lundbeck Foundation - Trust Deed and Governance - Grant policies - Centres of Excellence - Interaction between Foundation controlled pharma industry, university research and biotech cluster March 2006 Lundbeck Foundation TheThe DanishDanish ResearchResearch FundingFunding System*System* Private sector Euro 3,44 bn. 70% 1,78% of GNP Public sector Euro 1,49 bn. 30% 0,79% - - • Council for independent research Euro 124 m. • Council for strategic research Euro 47 m. • National research foundation Euro 27 m. • Technology foundation Euro 26 m. Private foundations**) Euro 134 m. (The Lundbeck Foundation contributes Euro 30 m.) *) Source: The Danish Centre for Studies in Research and Research Policy, some figures relate to 2003. **) Estimate 2005, included in public sector statistics. Lundbeck Foundation THETHE LUNDBECKLUNDBECK FOUNDATIONFOUNDATION • Established in 1954 by Mrs. Grete Lundbeck (no descendants) • Owns 70% of the listed pharmaceutical company H. Lundbeck A/S • An industrial foundation regulated under The Commercial Foundations Act. • Several large Danish companies are controlled by industrial foundations • The Lundbeck Foundation operates independently of its industrial subsidiary/founder family - no company executives on the Board/management - no grants given to company • The Lundbeck Foundation provides grants to research of Euro 30 m. H. Lundbeck A/S has a R&D budget of Euro 250 m. • The Lundbeck Foundation’s asset base is Euro 4 bn. – 65% hereof in donor stock Lundbeck Foundation SeveralSeveral foundationfoundation--ownedowned companiescompanies amongamong thethe largestlargest DanishDanish firmsfirms • A.
    [Show full text]
  • Popular Employer Names Number of Data Profiles Blackrock, Inc. 43
    S.No Popular Employer Names Number of Data Profiles 1. Blackrock, Inc. 43 2. BMC Software, Inc. 55 3. BNP Paribas Inc. 113 4. BRISTLECONE India Ltd 57 5. British Telecom 131 6. Broadcom Corporation 59 7. Broadridge Financial Solutions, Inc. 44 8. Bureau Veritas 47 9. CA Technologies 65 10. CA, Inc. 39 11. Cairn India 45 12. Calsoft Pvt Ltd 44 13. Capgemini 1,309 14. Capgemini Consulting 578 15. Capita india 82 16. Capital Iq, Inc. 41 17. Caterpillar, Inc. 75 18. CBRE Group 60 19. CenturyLink 47 20. Cerner Corporation 65 21. CGI Group Inc. 300 22. Cipla Medpro Manufacturing 43 23. Cisco Systems (India) Private Limited 57 24. Cisco Systems Inc 396 25. Citibank 235 26. Citigroup, Inc. 53 27. CitiusTech 59 28. Citrix Systems Inc 40 29. CMC Group 102 30. Cognizant 1,374 31. Cognizant Technology Solutions Corp 1,715 32. Collabera Inc. 74 33. Computer Sciences Corporation (CSC) 653 34. Concentrix Corporation 159 35. Convergys Corporation 113 36. Credit Suisse 90 37. Crisil 117 38. CTS Corporation 109 39. Cummins India Ltd 70 40. Cvent, Inc. 46 41. Cybage 201 42. Daimler India Commercial Vehicles Pvt Ltd 61 43. Dell, Inc. 516 44. Deloitte 414 45. Deloitte & Touche LLP 107 46. Deloitte Consulting LLP 282 47. Deloitte Support Services India Private Ltd 94 48. Deloitte Touche Tohmatsu (DTT) 79 49. Deutsche Bank 235 50. Dimension Data 63 51. Directi 44 52. Dr Reddy's Laboratories Ltd 85 53. Dun & Bradstreet Corp 50 54. E.I. Du Pont De Nemours & Co (DuPont) 47 55.
    [Show full text]